Mesa Laboratories (MLAB) Expected to Announce Quarterly Earnings on Tuesday

Mesa Laboratories (NASDAQ:MLAB) is expected to issue its Q3 2026 results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of $2.41 per share and revenue of $63.2330 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Tuesday, February 3, 2026 at 8:00 AM ET.

Mesa Laboratories Stock Performance

Shares of NASDAQ MLAB opened at $81.72 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 2.02 and a debt-to-equity ratio of 0.95. The firm’s 50-day moving average price is $80.54 and its two-hundred day moving average price is $74.39. Mesa Laboratories has a 52-week low of $55.45 and a 52-week high of $155.12. The stock has a market capitalization of $451.09 million, a P/E ratio of -255.38 and a beta of 0.89.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Saturday, February 28th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 annualized dividend and a dividend yield of 0.8%. Mesa Laboratories’s dividend payout ratio (DPR) is -200.00%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on MLAB shares. Wall Street Zen upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a report on Thursday. Zacks Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Finally, Wells Fargo & Company increased their price objective on shares of Mesa Laboratories from $75.00 to $83.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $83.00.

Institutional Investors Weigh In On Mesa Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of MLAB. Jacobs Levy Equity Management Inc. bought a new position in Mesa Laboratories in the 3rd quarter valued at about $258,000. Qube Research & Technologies Ltd raised its position in shares of Mesa Laboratories by 54.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 30,725 shares of the medical instruments supplier’s stock worth $2,059,000 after buying an additional 10,827 shares in the last quarter. Numerai GP LLC acquired a new stake in shares of Mesa Laboratories in the 3rd quarter worth approximately $242,000. Millennium Management LLC boosted its holdings in shares of Mesa Laboratories by 131.9% in the third quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock valued at $8,967,000 after acquiring an additional 76,107 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in shares of Mesa Laboratories by 27.2% during the third quarter. Citadel Advisors LLC now owns 34,178 shares of the medical instruments supplier’s stock valued at $2,290,000 after acquiring an additional 7,305 shares during the period. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.